Last updated: 2026-10-12 13:44:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Jazz Pharmaceuticals, Inc. (JAZZ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $218.73, with a market capitalisation of $14.18B and a P/E ratio of 15.07. Over the past 52 weeks, its price has ranged from $128.80 to $266.38. This page covers its latest market performance, valuation, price trends and company information.
$14.18B | |
$218.51 | |
$266.38 | |
$0.52 | |
$218.42 | |
24.58K | |
870.04K | |
15.07 | |
$266.38 | |
$128.80 | |
-- | |
-- |
Jazz Pharmaceuticals, Inc. (JAZZ) is currently trading at $218.73 as of 2026-10-12 13:43:00, up 0.14% ($0.31) from the previous close of $218.42
During today's regular trading session, JAZZ has traded between $0.52 and $266.38, with a trading volume of 24.58K shares. The current price is near the upper end of today's range.
Over the past seven days, Jazz Pharmaceuticals, Inc. (JAZZ) moved from $233.01 to $218.73, representing a decline of 6.13% ($14.28).
The stock traded between $213.20 and $238.87 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 888.57 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 65.4%
JAZZ is currently trading at $218.73, placing it 65.4% of the way from its 52-week low of $128.80 to its 52-week high of $266.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2890 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jazz Pharmaceuticals, Inc. (JAZZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.